PATENT CLAIM ANALYSIS

Application Number: 16054728
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["544", "343000"]

Abstract:
This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT 2A  receptor, serotonin transporter (SERT) and/or pathways involving dopamine D 1 /D 2  receptor signaling systems, and/or the treatment of residual symptoms.

Claim (Index 20):
The method of  claim 18 , wherein the one or more other therapeutic agents are antipsychotic agents selected from chlorpromazine, haloperidol, droperidol, fluphenazine, loxapine, mesoridazine molindone, perphenazine, pimozide, prochlorperazine promazine, thioridazine, thiothixene, trifluoperazine, clozapine, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone, asenapine, lurasidone, iloperidone, cariprazine, amisulpride, zotepine, sertindole, in free or pharmaceutically acceptable salt form.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 96.0
- Lexical Diversity: 1.29091
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15301895', '16088397', '15301912', '14394467', '15629481']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8084404740780122
- 35 USC 102 Novelty (BERT): 0.5549046186698211
- Combined Prediction Score: 0.7830868885371932
- Mean Citation Score: 377.4376160000001
- Max Citation Score: 431.4497
- Similarity Product: 373.3395200748087

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test